ALX Oncology’s Acquisition of ScalmiBio

Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the deal.

ALX Oncology Holdings Inc. (ALX Oncology), a clinical-stage immuno-oncology company, and ScalmiBio, Inc., announced that ALX has acquired ScalmiBio. 

ALX Oncology will further expand its pipeline  by developing new anti-cancer drug candidates based on ScalmiBio’s platform; these new molecules will be designed to address unmet cancer patient needs as stand-alone therapeutics and in combination with ALX Oncology’s lead product candidate, evorpacept, a next-generation CD47 blocker designed to leverage the immune activation of broadly used anti-cancer agents through combination strategies. ALX Oncology has also acquired ScalmiBio’s proprietary cytotoxic payloads for the development of ADCs.

The Wilson Sonsini team that advised ALX Oncology on the transaction includes Michael Coke (Picture), Scott McCall, Myra Sutanto Shen, Jackie Tokuda, Rebecca Stuart, John Krocak, Tracy Sevush, Sara Dunton, Jason Chan, David Lee, Abhinaya Prithivi, and Kexi Wang.

Involved fees earner: Jason Chan – Wilson Sonsini Goodrich & Rosati; Michael Coke – Wilson Sonsini Goodrich & Rosati; Sara Dunton – Wilson Sonsini Goodrich & Rosati; John Krocak – Wilson Sonsini Goodrich & Rosati; Scott McCall – Wilson Sonsini Goodrich & Rosati; David Seoho Lee – Wilson Sonsini Goodrich & Rosati; Tracy S. Sevush – Wilson Sonsini Goodrich & Rosati; Rebecca Stuart – Wilson Sonsini Goodrich & Rosati; Myra Sutanto Shen – Wilson Sonsini Goodrich & Rosati; Jaqueline Tokuda – Wilson Sonsini Goodrich & Rosati; Kexi Wang – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: ALX Oncology Holdings Inc.;

Author: Martina Bellini